| 1. |
|
|
| 2. |
- Cucarella, Victor, et al.
(author)
-
Recycling of calcium-silicate material after wastewater filtration to agriculture -Soil condition impact
- 2012
-
In: Ecological Chemistry and Engineering S. - : Walter de Gruyter GmbH. - 1898-6196. ; 19:3, s. 373-382
-
Journal article (peer-reviewed)abstract
- Reactive filter materials aimed at phosphorus (P) recovery is a novel method for on-site wastewater treatment. Once the bed filter is no longer effective, the sorbent must be replaced and can then be recycled as a soil amendment to agriculture. This study investigated the short-term effects of such amendments in a field with a wheat crop in order to evaluate the risks and/or potential benefits of this disposal option. The developed product Polonite (manufactured from Opoka) was used as a model filter sorbent in the field trial. Rates corresponding to approximately 6 and 8 tons per hectare were applied. In the short-term, this amending did not affect soil physical and sorption properties. The rate of Polonite used here, as P source for wheat was irrelevant in this kind of soil. The usefulness of this disposal option of exhausted filter material is discussed.
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
- Gerotziafas, GT, et al.
(author)
-
Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine
- 2020
-
In: Thrombosis and haemostasis. - : Georg Thieme Verlag KG. - 2567-689X .- 0340-6245. ; 120:12, s. 1597-1628
-
Journal article (peer-reviewed)abstract
- COVID-19 is also manifested with hypercoagulability, pulmonary intravascular coagulation, microangiopathy, and venous thromboembolism (VTE) or arterial thrombosis. Predisposing risk factors to severe COVID-19 are male sex, underlying cardiovascular disease, or cardiovascular risk factors including noncontrolled diabetes mellitus or arterial hypertension, obesity, and advanced age. The VAS-European Independent Foundation in Angiology/Vascular Medicine draws attention to patients with vascular disease (VD) and presents an integral strategy for the management of patients with VD or cardiovascular risk factors (VD-CVR) and COVID-19. VAS recommends (1) a COVID-19-oriented primary health care network for patients with VD-CVR for identification of patients with VD-CVR in the community and patients' education for disease symptoms, use of eHealth technology, adherence to the antithrombotic and vascular regulating treatments, and (2) close medical follow-up for efficacious control of VD progression and prompt application of physical and social distancing measures in case of new epidemic waves. For patients with VD-CVR who receive home treatment for COVID-19, VAS recommends assessment for (1) disease worsening risk and prioritized hospitalization of those at high risk and (2) VTE risk assessment and thromboprophylaxis with rivaroxaban, betrixaban, or low-molecular-weight heparin (LMWH) for those at high risk. For hospitalized patients with VD-CVR and COVID-19, VAS recommends (1) routine thromboprophylaxis with weight-adjusted intermediate doses of LMWH (unless contraindication); (2) LMWH as the drug of choice over unfractionated heparin or direct oral anticoagulants for the treatment of VTE or hypercoagulability; (3) careful evaluation of the risk for disease worsening and prompt application of targeted antiviral or convalescence treatments; (4) monitoring of D-dimer for optimization of the antithrombotic treatment; and (5) evaluation of the risk of VTE before hospital discharge using the IMPROVE-D-dimer score and prolonged post-discharge thromboprophylaxis with rivaroxaban, betrixaban, or LMWH.
|
|
| 6. |
- Plouin, PF, et al.
(author)
-
A clinical approach to the management of a patient with suspected renovascular disease who presents with leg ischemia
- 2003
-
In: International Angiology. - 1827-1839. ; 22:4, s. 333-339
-
Research review (peer-reviewed)abstract
- Athernsclerotic renal artery stenosis (ARAS) may cause hypertension, progressive renal failure, and recurrent pulmonary edema. It typically occurs in high risk patients with coexistent vascular disease elsewhere. Most patients with ARAS are likely to die from coronary heart disease or stroke before end-stage renal failure occurs. Recent controlled trials have shown that most patients undergoing angioplasty to treat renovascular hypertension still need antihypertensive agents 6 or 12 months after the procedure. Nevertheless, the number of antihypertensive agents required to control blood pressure adequately is lower following angioplasty than for medication alone. Trials assessing the value of revascularization for preserving renal function or preventing clinical events are only in the early recruitment phase. Revascularization should be undertaken in patients with ARAS and resistant hypertension or heart failure, and probably in those with rapidly deteriorating renal function or with an increase in plasma creatinine levels during angiotensin-converting enzyme inhibition. With or without revascularization, medical therapy using antihypertensive, hypolipidemic and antiplatelet agents is necessary in almost all cases.
|
|
